N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Endocrine Tumors
Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001
Phase 2 N=45 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
Phase 2 N=46 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Gastrointestinal Carcinoid Tumor · Islet Cell Tumor · Neoplastic Syndrome
Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001
Phase 3 N=85 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Phase 2 N=122 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Phase 2 N=15 Lithium for Low-Grade Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 0; 8 participants
Phase 2 N=29 Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months
N/A N=399 Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Phase 2 N=97 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
Phase 3 N=204 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
Non Functioning Entero-pancreatic Endocrine Tumour
Primary: Adverse Events — 40; 46; 86 participants with any TEAEs
Phase 2 N=60 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 3 N=11 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed
Phase 2 N=36 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Phase 2 N=83 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Neoplasms
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 52.9; 53.1 percentage of participants
Phase 2 N=9 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Phase 3 N=108 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly
Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…
Phase 2 N=93 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Phase 2 N=111 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants
Phase 2 N=28 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=41 Capecitabine and Temozolomide for Neuroendocrine Cancers
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Phase 2 N=1,553 Studies of Elevated Parathyroid Activity
Hyperparathyroidism · Hypercalcemia · Parathyroid Neoplasm
Primary: Type of Hyperparathyroidism — 90; 276; 19; 61 Participants